Search
for
Sort by
Research 211–240 of 1000+
- P63 targeted deletion under the FOXN1 promoter disrupts pre-and post-natal thymus development, function and maintenance as well as induces severe hair loss
- Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial)
- Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial
- Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial
- 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men
- Anterior, frontal congenital triangular alopecia, redundancy in therapy without improvement
- α<sub>1</sub>-AR agonist induced piloerection protects against the development of traction alopecia
- Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial.
- Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial).
- Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil treatment in Brazilian female pattern hair loss patients
- Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil.
- Review of systemic methotrexate therapy in pediatric dermatoses
- Novel topical booster enhances follicular sulfotransferase activity in patients with androgenetic alopecia: a new strategy to improve minoxidil response
- Novel shampoo reduces hair shedding by contracting the arrector pili muscle via the trace amine‐associated receptor
- Electronic Circular Dichroism Imaging (ECD <i>i</i> ) Casts a New Light on the Origin of Solid‐State Chiroptical Properties
- Microneedling improves minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes.
- Identification of the sulfotransferase iso-enzyme primarily responsible for the bio-activation of topical minoxidil.
- Platelet Rich Plasma in Androgenic Alopecia: Where do we Stand?
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Hair follicle sulfotransferase activity and effectiveness of oral minoxidil in androgenetic alopecia
- SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth
- Scalp neuropathy in androgenetic alopecia
- Clinical Diagnosis of COVID-19: a Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1,757-Patient Cohort (The AndroCoV Clinical Scoring for COVID-19 Diagnosis).
- Clinical diagnosis of COVID-19: a prompt, feasible, and sensitive diagnostic tool for COVID-19 based on a 1,757-patient cohort (The AndroCoV Clinical Scoring for COVID-19 diagnosis)
- Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial).
- Novel “After Minoxidil” spray improves topical minoxidil compliance and hair style manageability
- Can we halt male androgenetic alopecia progression without antiandrogenic drugs?
- 841 Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical Minoxidil
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- Hair analysis of formoterol as a novel tool to assess long‐term inhalation medication adherence: Data from the TRICOLON trial